---
title: "Repatha (evolocumab) in cardiovascular event risk reduction: Clinical trials questions"
description: "Clinical trials questions on Repatha (evolocumab) in cardiovascular event risk reduction, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Cardiovascular outcomes and Study results. Questions: Does Repatha reduce heart attacks and strokes in established cardiovascular disease (FOURIER)? Did Repatha lower the risk of death in FOURIER? Does Repatha reduce cardiovascular events without a prior heart attack or stroke (VESALIUS-CV)? Did Repatha lower the risk of death in VESALIUS-CV? 2 further questions follow. 6 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/clinical-trials"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Repatha (evolocumab) in cardiovascular event risk reduction: Clinical trials questions

Manufacturer: Amgen Inc.  
Prescribing information: [Repatha](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf)

Questions that apply to every indication of Repatha are on [Repatha (evolocumab), all indications](https://www.evicenter.com/medical-information/repatha).

## Cardiovascular outcomes

<a id="repatha-fourier-results"></a>

### Does Repatha reduce heart attacks and strokes in established cardiovascular disease (FOURIER)?

> “Trial 1 (FOURIER, NCT01764633) was a double-blind, randomized, placebo-controlled, event-driven 
> trial in 27,564 (13,784 REPATHA, 13,780 placebo) adult patients with established cardiovascular disease”

Source: [REPATHA: Prescribing information, page 12, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=12)

> “(CVD) and with LDL-C ≥ 70 mg/dL and/or non-HDL-C ≥ 100 mg/dL despite high- or moderate-intensity 
> statin therapy. Patients were randomly assigned 1:1 to receive either subcutaneous injections of 
> REPATHA (140 mg every 2 weeks or 420 mg once monthly) or placebo; 86% used the every-2-week 
> regimen throughout the trial. The median follow-up duration was 26 months. Overall, 99% of patients 
> were followed until the end of the trial or death.”

Source: [REPATHA: Prescribing information, page 13, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=13)

> “REPATHA significantly reduced the risk for the primary composite endpoint (time to first occurrence of 
> CV death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary 
> revascularization; p < 0.0001) and the key secondary composite endpoint (time to first occurrence of 
> cardiovascular death, myocardial infarction, or stroke; p < 0.0001).”

Source: [REPATHA: Prescribing information, page 13, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=13)

> “Table 3. Effect of REPATHA on CV Events in Patients with Established CVD in FOURIER 
>
>
> Placebo 
> REPATHA 
> REPATHA 
> vs. Placebo 
>
> N = 13,780 
> n (%) 
> Incidence 
> Rate (per 
> 100 
> patient 
> years) 
> N = 13,784 
> n (%) 
> Incidence 
> Rate (per 
> 100 
> patient 
> years) 
> Hazard 
> Ratio 
> (95% CI) 
>
> Primary composite endpoint  
> Time to first occurrence of 
> CV death, myocardial 
> infarction, stroke, coronary 
> revascularization, 
> hospitalization for unstable 
> angina  
> 1,563 (11.3) 
> 5.2 
> 1,344 (9.8) 
> 4.5 
> 0.85  
> (0.79, 0.92) 
> Key secondary composite endpoint 
> Time to first occurrence of 
> CV death, myocardial 
> infarction, stroke  
> 1,013 (7.4) 
> 3.4 
> 816 (5.9) 
> 2.7 
> 0.80  
> (0.73, 0.88)”

Source: [REPATHA: Prescribing information, page 13, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=13)

> “Other secondary endpoints”

Source: [REPATHA: Prescribing information, page 14, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=14)

> “Time to first fatal or 
> non-fatal myocardial 
> infarction 
> 639 (4.6) 
> 2.1 
> 468 (3.4) 
> 1.6 
> 0.73  
> (0.65, 0.82) 
> Time to first fatal or 
> non-fatal stroke 
> 262 (1.9) 
> 0.9 
> 207 (1.5) 
> 0.7 
> 0.79  
> (0.66, 0.95) 
> Time to first coronary 
> revascularization 
> 965 (7.0) 
> 3.2 
> 759 (5.5) 
> 2.5 
> 0.78  
> (0.71, 0.86)”

Source: [REPATHA: Prescribing information, page 14, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=14)

Note: In Table 3 each row gives placebo n (%) and incidence rate per 100 patient-years, then REPATHA n (%) and incidence rate, then the hazard ratio (95% CI) for REPATHA vs placebo. The myocardial infarction, stroke, and coronary revascularization rows appear under "Other secondary endpoints" in Table 3, for which the label reports no p-values. Patients in FOURIER had established cardiovascular disease and were on statin therapy.

<a id="repatha-fourier-death"></a>

### Did Repatha lower the risk of death in FOURIER?

> “Other secondary endpoints”

Source: [REPATHA: Prescribing information, page 14, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=14)

> “Time to CV death 
> 240 (1.7) 
> 0.8 
> 251 (1.8) 
> 0.8 
> 1.05  
> (0.88, 1.25) 
> Time to death by any 
> cause<sup>a</sup> 
> 426 (3.1) 
> 1.4 
> 444 (3.2) 
> 1.5 
> 1.04  
> (0.91, 1.19)”

Source: [REPATHA: Prescribing information, page 14, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=14)

> “<sup>a</sup> Time to death by any cause is not a component of either the primary composite endpoint or key secondary composite 
> endpoint.”

Source: [REPATHA: Prescribing information, page 14, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=14)

Note: Each row gives placebo (N = 13,780) n (%) and incidence rate per 100 patient-years, then REPATHA (N = 13,784) n (%) and incidence rate, then the hazard ratio (95% CI). FOURIER compared REPATHA 140 mg every 2 weeks or 420 mg once monthly with placebo, on a background of statin therapy, in patients with established cardiovascular disease over a median follow-up of 26 months.

<a id="repatha-vesalius-results"></a>

### Does Repatha reduce cardiovascular events without a prior heart attack or stroke (VESALIUS-CV)?

> “Trial 2 (VESALIUS-CV, NCT03872401) was a multicenter, double-blind, randomized, 
> placebo-controlled, parallel-group, cardiovascular outcomes trial to evaluate the effects of REPATHA in 
> 12,206 adult patients (6,106 REPATHA, 6,100 placebo) at high CV risk, including those with ASCVD or 
> diabetes mellitus (defined in the trial as diabetes of 10 or more years’ duration, treated with daily insulin, 
> or complicated by microvascular disease), who have not had a prior myocardial infarction or stroke. 
> Patients had to have an LDL-C ≥ 90 mg/dL or non-HDL-C ≥ 120 mg/dL or apolipoprotein B 
> (ApoB) ≥ 80 mg/dL on stable, lipid-lowering background therapy. Patients were randomly assigned 1:1 to 
> receive either subcutaneous injections of REPATHA (140 mg every 2 weeks) or placebo every 2 weeks. 
> The median follow-up duration was 55 months. Overall, 98% of patients were followed until the end of 
> the trial or death.”

Source: [REPATHA: Prescribing information, page 15, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=15)

> “REPATHA significantly reduced the risk for the primary composite endpoint (MACE-3: time to first 
> occurrence of coronary heart disease death, myocardial infarction, or ischemic stroke, p < 0.001) and the 
> other primary composite endpoint (MACE-4: time to first occurrence of coronary heart disease death, 
> myocardial infarction, ischemic stroke, or any ischemia-driven arterial revascularization, p < 0.001).”

Source: [REPATHA: Prescribing information, page 16, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=16)

> “Table 4. Effect of REPATHA on Cardiovascular Events in Patients at Increased Risk for 
> Cardiovascular Events in VESALIUS-CV 
>
> Placebo 
> (N = 6,100) 
> n (%) 
> REPATHA 
> (N = 6,106) 
> n (%) 
> Hazard Ratio<sup>1</sup> 
> (95% CI) 
> Primary MACE-3 composite endpoint 
> Time to CHD death, myocardial infarction, or 
> ischemic stroke, whichever occurred first<sup>a</sup> 
> 442 (7.3) 
> 336 (5.5) 
> 0.75 (0.65, 0.86) 
> Primary MACE-4 composite endpoint 
> Time to CHD death, myocardial infarction, 
> ischemic stroke, or any ischemia-driven arterial 
> revascularization, whichever occurred first<sup>a</sup> 
> 905 (14.8) 
> 746 (12.2) 
> 0.81 (0.73, 0.89)”

Source: [REPATHA: Prescribing information, page 16, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=16)

> “<sup>a</sup> Statistically significant, p-value <0.001.”

Source: [REPATHA: Prescribing information, page 17, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=17)

Note: In Table 4 each row gives placebo n (%), REPATHA n (%), and the hazard ratio (95% CI) for REPATHA vs placebo. VESALIUS-CV compared REPATHA 140 mg every 2 weeks with placebo on stable lipid-lowering background therapy over a median follow-up of 55 months.

<a id="repatha-vesalius-death"></a>

### Did Repatha lower the risk of death in VESALIUS-CV?

> “Time to CHD death<sup>2,3</sup> 
> 116 (1.9) 
> 105 (1.7) 
> 0.90 (0.69, 1.17) 
> Time to cardiovascular death<sup>2,3</sup> 
> 194 (3.2) 
> 156 (2.6) 
> 0.80 (0.65, 0.98) 
> Time to all cause of death<sup>2</sup> 
> 538 (8.8) 
> 432 (7.1) 
> 0.80 (0.70, 0.90)”

Source: [REPATHA: Prescribing information, page 17, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=17)

> “² Did not meet statistical significance according to the prespecified hierarchical testing procedure.”

Source: [REPATHA: Prescribing information, page 17, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=17)

> “³ First occurrence of specified event at any time; patients may have experienced more than one adjudicated event.”

Source: [REPATHA: Prescribing information, page 17, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=17)

Note: Each row gives placebo (N = 6,100) n (%), REPATHA (N = 6,106) n (%), and the hazard ratio (95% CI). The digits after each endpoint name are footnote markers; footnote 2 marks the endpoints that did not meet statistical significance under the hierarchical testing procedure. VESALIUS-CV compared REPATHA 140 mg every 2 weeks with placebo every 2 weeks on stable lipid-lowering background therapy in adults at high cardiovascular risk without a prior myocardial infarction or stroke, followed for a median of 55 months.

<a id="repatha-vesalius-heart-attack"></a>

### Does Repatha reduce heart attacks in patients without a prior heart attack (VESALIUS-CV)?

> “Time to cardiovascular death, MI, or ischemic 
> stroke<sup>a</sup> 
> 502 (8.2) 
> 374 (6.1) 
> 0.73 (0.64, 0.84)”

Source: [REPATHA: Prescribing information, page 16, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=16)

> “Time to MI<sup>a,3</sup> 
> 229 (3.8) 
> 149 (2.4) 
> 0.64 (0.52, 0.79)”

Source: [REPATHA: Prescribing information, page 16, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=16)

> “<sup>a</sup> Statistically significant, p-value <0.001.”

Source: [REPATHA: Prescribing information, page 17, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=17)

> “¹ Cox-proportional hazards model with treatment as a factor and stratified by the randomization stratification factors.”

Source: [REPATHA: Prescribing information, page 17, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=17)

> “³ First occurrence of specified event at any time; patients may have experienced more than one adjudicated event.”

Source: [REPATHA: Prescribing information, page 17, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=17)

Note: These are secondary endpoints of VESALIUS-CV (Table 4). Each row gives placebo (N = 6,100) n (%), REPATHA (N = 6,106) n (%), and the hazard ratio (95% CI); the letters and digits after each endpoint name are the footnote markers quoted below the rows. VESALIUS-CV compared REPATHA 140 mg every 2 weeks with placebo every 2 weeks on stable lipid-lowering background therapy in adults at high cardiovascular risk without a prior myocardial infarction or stroke, followed for a median of 55 months.

## Study results

<a id="repatha-ldl-cv-trials"></a>

### How much does Repatha lower LDL cholesterol in the cardiovascular outcomes trials?

> “The difference between REPATHA and placebo in mean percent change in LDL-C from baseline to 
> Week 12 was −63% (95% CI: −63%, −62%) and from baseline to Week 72 was 
> −57% (95% CI: −58%, −56%). At Week 48, the median [Q1, Q3] LDL-C was 26 [15, 46] mg/dL in the 
> REPATHA group, with 47% of patients having LDL-C < 25 mg/dL.”

Source: [REPATHA: Prescribing information, page 15, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=15)

> “Serial assessment of lipid panels was conducted for a subset of patients (n = 2,014) from randomly 
> selected sites and patients. The difference between REPATHA and placebo in mean percent change in 
> LDL-C from baseline to Week 48 was -53% (95% CI: -56%, -49%) and from baseline to Week 96 
> was -46% (95% CI: -50%, -43%). The resultant LDL-C values achieved at Week 48 were a median 
> (Q1, Q3) of 45 (26, 73) mg/dL and 109 (86, 144) mg/dL in the REPATHA and placebo arms, 
> respectively.”

Source: [REPATHA: Prescribing information, page 18, captured 2026-11-13](https://www.pi.amgen.com/united_states/repatha/repatha_pi_hcp_english_current.pdf#page=18)

Note: The first passage is from FOURIER (patients with established cardiovascular disease on statin therapy) and the second from VESALIUS-CV (patients at high cardiovascular risk without a prior myocardial infarction or stroke); both compare REPATHA with placebo. REPATHA was given as 140 mg every 2 weeks or 420 mg once monthly in FOURIER and as 140 mg every 2 weeks in VESALIUS-CV.

## Related pages
- [Medical information: Repatha (evolocumab): Cardiovascular event risk reduction](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction)
- [Indication](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/indication)
- [Safety](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/repatha--cardiovascular-event-risk-reduction/guidelines)
